Norse, it's like being stuck in the snow with no snow tires. Very frustrating how this stock can't gather any momentum. I'm beginning to wonder if FDA approval is already baked into current price.
This is not the forum that's going to be most effective to your cause. Try petitioning the institutional investors instead of the dozen or so retail investors that post on this thread. Maybe you can attend the next shareholder meeting ? Or maybe you can just sell the stock and invest in a company that has the attributes you're looking for, with all your years of experience I'm sure you will find one. Norse, you're wasting your time and energy on this site, you garnish no respect and you are making a fool of yourself.
Just sayin' , my friend.
Bignerd. If youre a beleiver are you in for the long haul? Or are you in for the trade?
You called it twice now. Good stuff!
Norse, just thought it needed repeating. Nothing has really changed here, but I'm am extremely disappointed with the direction management and the string pullers have decided to take. I still hold quite a bit of shares here and I'm hoping that this technology finds its way to the masses.
While we don’t want to appear to write off Biofire, given the company has an aggressive management team that has been very effective at commercializing its Respiratory Viral panel, when scientists and doctors study the difference between the two assays, Nanosphere should win the business based on both cost competitiveness and accuracy.
Now NSPH’s management needs to deliver on the commitment to receive FDA approval for the Gram Negative test to effectively address both important segments of bloodstream infections.
Had to past article. Won't let me post link.
From July 23 2013
Over the past month, shares of Nanosphere (NSPH) have sold off, we believe due to a competitor named Biofire (formerly Idaho Technology) receiving FDA approval for its Blood Culture assay. This was very expected by all with any knowledge of the multiplex molecular diagnostics industry, and it is the first test on the market that can challenge Nanosphere’s Gram Positive Panel, yet is uniquely different. Biofire’s Blood Culture ID Panel wraps up three of NSPH’s tests into one: Gram Positive Bacteria, Gram Negative Bacteria, as well as a Fungal Panel. So on the onset, it would appear this is a much more competitive panel than Nanosphere’s, since currently Nanosphere only has FDA approval for the Gram Positive segment of this assay (which is the most common type of bloodstream infection in the US).
But when you look a little closer, and call a few labs, the fact that all segments of a blood culture can be detected from one sample, and only on the same assay becomes a cost problem for the labs. Under both systems, labs still have to culture a blood sample, and nearly all labs we spoke with said that in the event a blood culture shows the patient does indeed have a bloodstream infection, they will gram stain the sample, since this is the first stage that allows a doctor to dose the patient on a better antibiotic than what she originally prescribed. If the patient’s culture stains purple, the doctor will be able to immediately identify it as a Gram-positive bloodstream infection, and adjust antibiotic treatment appropriately. Should the bacteria stain pink, the infection is a Gram-Negative bacteria (more common in Europe than in US), and would often require totally different antibiotics. After the stain is done, a lab will typically embark on a 12-24 hour process of identifying which genus and species the bacteria is, which helps to further treat the patient’s infection. NSPH’s instrument can get this answer in two hours, and Biofire’s can get the answer in just over an hour.
While timeliness is certainly important in the case of bloodstream infections, realizing that some of these patients could be minutes away from slipping into Sepsis, the difference of one hour will not change the initial dose of antibiotics the patient is put on once the gram stain identifies the type of infection. To most of the lab directors we’ve spoken with regarding rapid molecular tests, the sensitivity of the test is the most important consideration, with timeliness, ease of workflow and cost competitiveness not far behind. In the particular case of a bloodstream infection, getting false negatives can be a fatal problem. Sensitivity is of the utmost importance, given that a failure to appropriately identify an infection can lead to a Septic patient, likely resulting in death of the patient. A death that would be the result of an error of diagnosis.
This is why we’re so surprised that a lab would consider Biofire’s assay over Nanosphere’s. The sensitivity of the Gram Positive panel is only 95.8%, with the worst results in the most common infections. Nanosphere’s had a sensitivity of 98.4%, with 2/3 of the false negatives occurring in identifying the less-important contaminant of S. epidermidis. It’s hard to argue with the accuracy of Nanosphere’s test, but if that’s not enough, the price for the assay is only $65 vs. $130 for Biofire’s.
Well, William. I live in Canada. I will send gift basket I promised if there's a tuck.
Good luck to everyone next week, I'm going on Vacation.
R.R. Steen, Toronto ON Canada.
And to make things worse EVEREST, a pump publication, apparently has been pumping this thing, or so I hear. That is the worst possible scenario here. Might explain the last jump to the $2.15 level. I hope that I'm wrong, but this is not looking good. $100 Million market cap show no confidence in this company.
Norse, i think he's talking to me.. Richmando, you are obviously not paying attention to any of my posts, other than the one you commented on. If you decide to check any of my previous posts you will quickly learn that I am Long the stock and have been for almost 2 years. I also made comments that I will dispose of my position
On any rallies in this stock. I owned 23,000 shares and currently Sitting on 18,000 , average price $2.37. I know plenty about my investment, most of which has been discussed on this thread, but now it's all begging to look like smoke and mirrors. Not happy with management either but the real inane posts seem to be coming from others.